

J. Safra Sarasin

JSS Responsible Equity - India P EUR acc

Data as of 31 July 2023 | Source: JSS Investmentfonds Ltd | Page 1 of 2

Fund Overview

Net asset value per sh	nare 135.32
Fund size in millions	74.20
Investment company	J. Safra Sarasin Fund
	Management (Luxembourg) S.A.
Depositary	RBC Investor Services
	Bank S.A., Luxembourg
Portfolio management	UTI International (Singapore)
	Private Limited
Portfolio Manager	Ajay Tyagi
Domicile of fund	Luxembourg
ISIN code	LU2106615144
Swiss SecNo.	52 188 964
Launch date	29 September 2020
End of fiscal year	April
Ongoing charges	2.19%
Management fee	1.70%
Accounting currency	EUR
Dividend payment	none (reinvesting)
Sales fee	max. 3.00%
Exit charge	0.0%
Legal Structure	SICAV
Issue/Redemption	daily
Benchmark (BM) as lis	sted MSCI India Net Total
in the prospectus	Return Index

Statistical Ratios	Fund	Benchmark
Volatility	n.a.	n.a.
Beta	n.a.	n.a.
Sharpe Ratio	n.a.	n.a.
Information Ratio	n.a.	n.a.
Tracking Error	n.a.	n.a.

The statistical ratios will only be calculated on a reporting period of 36 months or more.

Risk and reward profile

SFDR Classification

_	lower risk			hı	gher ris	SK _	
typically lower rewards				typica	lly high reward		
	1	2	3	4	5	6	7

The risk and reward category shown is based on historical data and can not be used as a reliable indicator of the future risk profile of the fund. The classification of the fund may change over time and is not a guarantee.

Fund Portrait


The JSS Responsible Equity - India aims to deliver long-term capital growth. To achieve this, the sub-fund invests primarily in the equity of Indian companies. It will also systematically integrate financially-material ESG aspects throughout the entire investment process, in order to avoid controversial exposures, mitigate ESG risks and harness opportunities.

Net Performance (in EUR) as of 31.07.2023

1 Month

-0.33%

1.91%



left scale: right scale, annual performance in %:

Performance indexed Fund

 3 Months
 YTD
 1 year
 3 years p.a.
 5 years p.a.

 9.65%
 4.97%
 -6.11%
 n.a.
 n.a.

 11.11%
 4.78%
 -0.55%
 n.a.
 n.a.

Benchmark (BM): MSCI India Net Total Return Index

	2022	2021	2020	2019	2018 Since	Inception
Fund	-16.10%	34.63%	n.a.	n.a.	n.a.	35.32%
BM	-1.92%	35.82%	n.a.	n.a.	n.a.	62.42%

Past performance does not guarantee future returns. The performance shown does not take account of any commissions and costs charged when subscribing and redeeming units.

Top Ten Holdings

Fund

BM

HDFC Bank Ltd	7.29%
ICICI Bank Ltd	6.45%
LTI Mindtree Ltd	6.39%
Bajaj Finance Ltd	5.95%
Infosys Ltd	3.97%
Kotak Mahindra Bank Ltd	3.92%
Avenue Supermarts Ltd	3.69%
Info Edge (India) Ltd.	3.66%
Astral Poly Technik Ltd	3.11%
Coforge Limited	2.98%

Sector Allocation

26.59%	Financials
19.78%	Inform.Technology
13.56%	Consumer Discretionary
11.83%	Health Care
10.61%	Industrials
7.39%	Consumer Staples
6.68%	Materials
1.10%	TelecommServices
2.46%	Other



J. Safra Sarasin

JSS Responsible Equity - India P EUR acc

Data as of 31 July 2023 | Source: JSS Investmentfonds Ltd | Page 2 of 2

Review

CPI inflation in June 2023 rose marginally to 4.8%, compared to 4.3% in May. Food and beverages inflation increased to 4.6% (May: 3.3%), while fuel and light inflation moderated to 3.9% (May: 4.7%). Rural and urban inflation increased to 4.72% (May: 4.2%) and 4.96% (May: 4.3%), respectively. Core inflation (CPI excluding food and fuel) stood at 5.1% (May: 5.01%). As per the latest RBI data, foreign exchange reserves increased to USD 607.03 billion over the month. The USD appreciated by $\sim\!0.26\%$ over the month, closing at 82.25 INR/USD vs. 82.04 INR/USD last month. Healthy earnings growth for the first quarter of FY 2024, along with declining global inflation, helped the equity market maintain positive momentum. Sensex delivered a return of 2.80% over the month. Nifty delivered a return of 2.94% over the month. The key outperforming and underperforming sectors in the benchmark over the month were industrials and financial services, respectively. Gland Pharma Ltd outperformed the index, while Metropolis Healthcare Ltd underperformed the index.

Outlook

On the global front, it is becoming increasingly evident that the rate hike cycle is close to peaking, which is positive for growth assets such as equity. Resilience shown by large economies in the initial part of the year has prompted upwards revisions to global growth forecasts for 2023, which is a significant positive for the outlook of equities and reflected in equity market momentum. At the same time, expectations at the beginning of the year of a pick-up in economic growth in China seem to be running out of steam, prompting major global banks to revise down China's growth estimates. In comparison, India's stable economic parameters make it a more attractive destination to global investors, leading to higher capital flows. Domestically, corporate earnings announced so far support the expectations of steady revenues, with the benefit of declining input costs driving robust earnings growth. Equity valuations are still much lower than the peaks witnessed in the past and may become more attractive as earnings accumulation continues going forward.

Benchmark Disclaimer

Companies Inc. ("S&P") and is licensed for use by {Licensee}. Neither MSCI, S&P nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the posibility of such damages.

Legal notices - Edition Switzerland:

JSS Investmentfonds II SICAV is a UCITS organised as an open-ended investment company (société d'investissement à capital variable - "SICAV") under the law of Luxembourg, and is regulated by the Commission de Surveillance du Secteur Financier ("CSSF"). This fund is a sub-fund of JSS Investmentfonds II SICAV. It has been authorised for public marketing in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). The issuer of this factsheet is not in a position to provide details on any one-off and/or recurring commission paid to or received by the bank and/or the fund's broker in connection with this product. Source of performance figures: Sarasin Investmentfonds Ltd, Datastream & SIX. Performance was calculated on the basis of net asset values (NAV) and gross dividends reinvested. When calculating performance, all the costs charged to the fund were included to give the net performance. The performance shown does not take account of any commissions and costs charged at the investor level when subscribing and redeeming units. Additional commissions, costs and taxes charged at the investor level have a negative impact on performance. The statements in this document neither constitute an offer nor an invitation to buy shares of the fund. All details are provided for marketing and information purposes only and should not be misinterpreted as investment advice. The latest prospectus, the key investor information document ("KIID"), the articles of incorporation as well as the annual and semi-annual reports are available free of charge from the paying agent (Bank J. Safra Sarasin Ltd, Elisabethenstrasse 62, P.O. Box, CH-4002 Basel) and the representative in Switzerland (J. Safra Sarasin Investmentfonds Ltd, Wallstrasse 9, CH-4002 Basel). The latest available prospectus as well as the KIID should be consulted before considering any investment. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. Due to the information in this document coming partially from third party sources, the accuracy, completeness or correctness of the information contained in this publication cannot be guaranteed. Persons domiciled in the USA or US nationals are not permitted to hold shares in JSS Investmentfonds II SICAV, and shares in JSS Investmentfonds II SICAV may not be publicly sold, offered or issued to anyone residing in the USA or to US nationals. This publication is intended only for investors in Switzerland. Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. The return upon the investment will therefore necessarily be variable. Consequently, there is no guarantee that investors will get back the full amount of their invested capital upon redemption. Investments in foreign currencies may run a currency risk, as the return in the investor's reference currency may be smaller or greater as a result of currency fluctuations. This document constitutes marketing material. If it refers to a financial instrument for which a prospectus and/or a key investor/information document exists, these are available free of charge from Bank J. Safra Sarasin Ltd, Elisabethenstrasse 62, P.O. Box, CH-4002 Basel, Switzerland.